| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dept of Child Health, University of Leicester, Leicester, UK
CORRESPONDENCE: S. Kotecha, Dept of Child Health, University of Leicester, Leicester, LE2 7LX, UK. Fax: 44 1162523282/2585502
Keywords: bronchoalveolar lavage fluid, bronchopulmonary dysplasia, chronic lung disease of prematurity, epidermal growth factor, growth factors, vascular endothelial growth factor
Received: October 9, 2000
Accepted July 5, 2001
This study was funded in part by Action research and the British Lung Foundation.
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionAcknowledgementsReferences |
|---|
The concentration of these growth factors was determined in 111 bronchoalveolar lavage fluid (BALF) samples from 35 ventilated infants: 13 developed CLD (median gestation 27 weeks, birthweight 820 g), 16 developed and recovered from respiratory distress syndrome (RDS) (31 weeks, 1,415 g) and six control infants (33 weeks, 2,075 g) were ventilated for nonpulmonary reasons.
At birth, EGF in BALF from the CLD and RDS infants was lower than in the control infants (control versus CLD, 7.3 versus 0.0 pg·mL–1, p<0.01; control versus RDS, 7.3 versus 5.0, p=0.08). EGF increased in all groups with a more rapid increase in control infants. A close relationship was noted between BALF EGF and gestational age (R=0.73). VEGF was undetectable at birth but increased at a similar rate in all three groups and did not correlate with gestation.
In conclusion, these data suggest that epidermal growth factor is closely correlated to gestation and that it may predispose preterm infants to develop chronic lung disease.
Chronic lung disease (CLD) of prematurity remains a major cause of morbidity and mortality in preterm infants 1. Recent advances including high frequency ventilation and nitric oxide have had a minimal impact on its incidence. Pulmonary inflammation appears to be an important risk factor for the development of CLD 2. Inflammation is mediated by neutrophils and all agents associated with neutrophil recruitment and activation including pro-inflammatory cytokines, soluble adhesion molecules, chemokines, neutrophil products, e.g. elastase and reactive oxygen species, have all been reported to be increased in infants who develop CLD 2. Sufficient evidence now exists to implicate lung inflammation as contributing to the development of CLD.
Inflammation is followed by resolution, repair and remodelling. Growth factors such as platelet-derived growth factor, insulin-like growth factors and transforming growth factor-;ß promote synthesis and deposition of the extracellular matrix and others such as epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) promote proliferation and maturation of epithelial and endothelial cells respectively. EGF is a small polypeptide (6 kDa) of 53 amino acid residues 3 and promotes mitogenesis and growth of all epithelial cell types. Increasing evidence supports its role in normal lung development and in maturation of epithelial cells in late gestation 4–6. In rat and human lung explants, EGF has been shown to increase surfactant phospholipid synthesis 7 and production of surfactant protein A 8, respectively. Administration of EGF to foetal rabbits and nonhuman primates accelerates lung maturation with decreased respiratory disease in the newborn animal 9. EGF clearly has a role to play in normal lung development and may also have a role to play in CLD where large areas of the epithelial barrier are injured.
Similarly, VEGF, a glycoprotein of 45 kDa, is a specific endothelial cell mitogen which has been shown to be increased in hypoxia 10. It also increases vascular permeability. Although its messenger ribonucleic acid (mRNA) is also present in other cell types, especially epithelial cells and smooth muscle cells, its site of action is specific to endothelial cells. VEGF appears to play a role in the remodelling of the pulmonary arteries after birth and in resolution of acute lung injury 11. Thus VEGF is an important factor for vascular maturation and may play a role in the repair processes that follow the lung inflammation that has been reported in CLD 2.
As the epithelial barrier is often injured in CLD, EGF would be expected to be increased in the reparative phase of CLD. Similarly, VEGF may be important in remodelling of the endothelium, especially in the pulmonary arteries, thus both growth factors would be expected to be increased in the lungs of infants who developed CLD. This study focused on EGF and VEGF in bronchoalveolar lavage fluid (BALF) obtained from infants who developed CLD, compared to infants who developed and recovered from respiratory distress syndrome (RDS) and to control infants requiring mechanical ventilation for nonpulmonary reasons.
|
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
Infants were excluded if there was documented or suspected evidence of infection at birth (i.e. with positive blood cultures) endotracheal tube secretion cultures or increased white cell count or C-;reactive protein (CRP). Infants were also excluded if there were any congenital anomalies that may have influenced lung architecture (e.g. infants with congenital diaphragmatic hernia, tracheo-oesophageal fistula or cystic adenomatous malformations). None of the infants had received postnatal corticosteroids during the study period. Informed written consent was obtained from parents to perform bronchoalveolar lavage on infants whilst intubated and receiving mechanical ventilation. The study was approved by the local research ethics committee.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed using a nonbronchoscopic technique at the time of clinically indicated tracheal suctioning, as previously described 12–15. Two aliquots of 1 mL·kg–1 (maximum 2 mL) of saline were instilled and immediately aspirated. Infants were lavaged twice weekly for 4 weeks or until extubation, whichever occurred earlier. The collected BAL samples were placed on ice and centrifuged at 500xg at room temperature for 10 min, within 10 min of collection. After centrifugation, the supernatant was collected and stored at –70°C until VEGF and EGF were estimated.
Measurement of concentration of epidermal growth factor and vascular endothelial growth factor
The concentration of EGF and VEGF was measured with commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (R&D Systems, Abingdon, Oxfordshire, UK). The lowest sensitivity of the kits were 0.7 pg·mL–1 and 9 pg·mL–1, respectively, for EGF and VEGF. The calibration standard curves for all plates with each growth factor had an R2-;value of >0.97.
Statistics
The concentration of both EGF and VEGF is presented as median values in pg·mL–1 for each diagnostic group against time. As recommended by the European Respiratory Society's guidelines for BAL in paediatrics including neonates 12, the data is presented as per mL of lavage fluid rather than per mL of epithelial lining fluid, since the estimation of the latter is inaccurate with current methods. Birth weight, gestation, fraction inspired oxygen, peak inspiratory pressure, oxygenation index and concentration of EGF and VEGF were compared between the three groups using the nonparametric analysis of variance (ANOVA), Kruskal-Walis and individual paired comparisons were made using the nonparametric Mann-Whitney U-;test. A p-;value <0.05 was considered significant.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
. From 29 infants developing respiratory failure, 13 infants developed chronic lung disease (CLD) (nine male and four female), and 16 developed and recovered from acute RDS (nine male and seven female). Six infants (five male, one female) requiring mechanical ventilation and inspired oxygen of <28% were also studied (four for abdominal surgical reasons, one for mild asphyxia and one for apnoea). Antenatal corticosteroids were given to 12 (92%) mothers of the CLD group, eight (50%) of the RDS group and two (33%) of the control group. Endotracheal natural surfactant was given to all but one infant in each of the CLD (92%) and RDS (94%) groups, whilst no infants in the control group received it.
|
). In contrast, in the RDS and control groups the EGF concentration was 5 pg·mL–1 and 7.3 pg·mL–1, respectively, immediately after birth. In both groups there was an increase in EGF with age, reaching 55.1 pg·mL–1 by 21 days old in the RDS infants and 101.3 pg·mL–1 by 10 days old in the control infants (fig. 1). Since decreased EGF may predispose the infant to respiratory failure, EGF concentration was compared in BALF from infants who did and did not develop CLD (fig. 2). Significant differences were found between the CLD infants and control infants (p<0.05), as well as between the CLD infants and those infants who did not develop CLD (p<0.05, fig. 2). At 4 days old, the difference only approached significance when the CLD and non-CLD infants were compared (p=0.07).
|
|
) and birth weight to determine whether a relationship existed. The concentration of EGF in the first lavage sample (which would reflect the infant's gestational age without postnatal influences) appeared to be related to gestational age (r=0.73, p<0.001) and a weaker relationship was noted for birth weight (r=0.63, p<0.001).
|
). The VEGF concentration increased to 212 pg·mL–1 in the CLD infants and 165.2 pg·mL–1 in the RDS infants by 4 days old, but remained undetectable in the control group (CLD versus control p<0.05, RDS versus control p<0.05). Thereafter, it increased gradually in the CLD and RDS groups to 679 pg·mL–1 and 768 pg·mL–1 respectively, but increased more rapidly in the control group to 873 pg·mL–1 by 10 days old. There was no relationship between concentration of BALF, VEGF and gestational age or birthweight (data not shown).
|
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
With improvements in neonatal care, the preterm infants are more likely to develop CLD than more mature infants who develop but recover from RDS. The relationship between gestation and EGF concentration is therefore interesting. EGF is known to promote maturation of type-II pneumocytes and subsequent production of components of surfactant 7, 8. It is interesting that CLD develops despite treatment with exogenous surfactant. In the present study, it was unclear whether the infants would have benefited from additional doses of surfactant given at a later stage e.g. at 5 days old or until the infants had synthesized sufficient endogenous surfactant. There is some evidence to suggest that additional doses of surfactant beyond the first few days of life may improve oxygenation 16.
In all three groups, EGF increased with time, probably reflecting a natural maturation of the infant exposed to the postnatal environment. The factors resulting in such an increase are likely to be the relatively hyperoxic postnatal environment as well as the natural increase of corticosteroids that occurs prior to delivery. Both antenatal and postnatal corticosteroids have been shown to promote maturation of type II cells 17. Scott et al. 18 reported increased urinary EGF in infants with CLD who responded to dexamethasone when compared to those who did not. In the present study, the infants had not received early postnatal corticosteroids; therefore, these were unlikely to be responsible for the increase in EGF. Antenatal corticosteroids are unlikely to have been responsible for the postnatal increase in the EGF, since all infants whose mothers had or had not received antenatal corticosteroids had similar increases postnatally.
In cell culture systems, EGF appears to accelerate the maturation of type II cells and the synthesis of components of the surfactant system 19. In nonhuman primates, prenatal foetal treatment with EGF appears to decrease the incidence and severity of RDS by increasing maturation of type II pneumocytes and by the subsequent increase of surfactant 20. In human infants it is recognized that most immature infants develop RDS and are at most risk of developing CLD. The present results show a relative deficiency of EGF in the first lavage sample obtained from infants, who subsequently developed CLD, and this corroborates evidence from animal models that implicate EGF as an important growth factor in the development of RDS. Whether strategies to increase EGF antenatally promote maturation of the foetal epithelium and better prepare the extremely preterm newborn infant to successful postnatal adaptation remains speculative.
Unlike EGF, no differences were found between the groups for BALF VEGF. However, like EGF, VEGF increased rapidly with time in agreement with previous reports of VEGF in preterm infants 21, 22. VEGF has repeatedly been shown to increase with hypoxia. However, in addition to the relative hyperoxic postnatal environment, the newborn infant undergoes many other changes including a transformation from the foetal to "adult-type" circulation. It is conceivable that such pressure changes may exert a greater influence on VEGF production postnatally since mechanical shear stress forces have been shown to increase VEGF release 23.
In contrast to EGF, no differences could be detected in VEGF between the groups at birth, although a maximum concentration was achieved earlier in the control group (fig. 4
). In addition, no differences between the concentration of VEGF in lung lavage fluid and either gestational age or birth weight were detected (data not shown). As VEGF has clearly been shown to increase vascular permeability it might be expected that this growth factor contributes to the protein deficiency that has been previously reported in infants who develop CLD 24.
In summary, the data suggests that epidermal growth factor was decreased at birth in infants who developed chronic lung disease. However, this decrease may simply reflect the immaturity of the infants who are at risk of developing chronic lung disease. A similar gestational effect was not seen for vascular endothelial growth factor. It was reassuring to note that infants at all gestations increased their pulmonary vascular endothelial growth factor and epidermal growth factor with time.
|
Acknowledgements |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or progressed to chronic lung disease (CLD) of prematurity (•), and infants who required mechanical ventilation for nonpulmonary reasons (control: 
). *: p<0.05 when CLD group compared to control infants and to those infants who do not progress to CLD.
